Vol 13, No 1 (2016)

Background. To study the peculiarities of pregnancy in asthma women and the health status of their children. Materials and methods. We examined the natural course and outcomes of pregnancy of 1010 women with asthma and monitored health status of their children up to 7 years old. Women were under the observation of pulmonologist and obstetrician throughout the period of gestation; they were treated if necessary and provided with recommendations for the primary prevention of allergic diseases in unborn child. Immediately after delivery children were under the supervision of a pediatrician, allergist. Results. Rising incidence of pregnancy complications in patients with asthma is directly related to the lack of control of the disease, especially in the first trimester of gestation. The lack of adequate treatment of asthma increases the risk of threatened abortion (OR 1,76, CI 0,90-3,47), preeclampsia (OR 2,77, CI 0,94-8,14), placental insufficiency (OR 2,45, CI 1,04-5,87), which has a direct effect on the formation of allergic diseases and, particularly, asthma in their children. Conclusion. Even severe asthma, is not a contraindication for pregnancy. The basic condition for the safety pregnancy and delivery is the adequate medical care that is a set of preventive and therapeutic measures for control of the disease that improve the quality of life of women during gestation and reduce the risk of allergic disease in their children.

Replacement immunotherapy with intravenous immunoglobulin (IVIG) has been used successfully for the treatment of primary immunodeficiency (PID) for over 60 years. During this time, a huge step forward in purification and manufacturing methods has been made. In addition IVIG therapy has been approved for other diseases and this number is steadily expanding causing an appearance of new IVIG on the pharmaceutical market. These drugs vary in composition, manufacturing technology and, as a consequence, in safety, administration rate, and efficacy. The new IVIG on the Russian market IG Vena was recently introduced. It has already proved its safety and efficacy abroad. This article presents the experience of using the drug IG Vena in adults with PID in immunopathology department of the Institute of Immunology FMBA Russia.

A food allergy is an abnormal immune response to food, mostly depended on IgE-mediated reactions. One of the most common symptoms of children’s food allergy is atopic dermatitis. The primary goal of diet therapy is the correct choice of hypoallergenic formula. In this article the cases of using amino-acid based formula «Neocate Advance»® in treatment of children with severe atopic dermatitis and cow’s milk food allergy are considered.

The article presents data about the role of such important essential trace element Zinc in the pathogenesis of atopic dermatitis (AD) and the use of zinc - preparations in the complex treatment of AD patients.

Background. Comparative study of clinical and immunological efficiency of systemic [with desloratadine (Aerius®, Bayer n=28)] and topical [with azelastin (Allergodil®, Meda Pharma) n=28] antihistamine single-agent treatment of persistent allergic rhinitis in primary school children (56 children from 6 to 11 years old) was carried out on the basis of monitoring the dynamics of nasal mucosa inflammatory biomarkers (IgE, sIgA, IL-4, IL-8, IL-13, IFN-y, TNFa). Materials and Methods. Questionnaires, selfmonitoring diaries with daily score-based assessment of the symptoms and the score of used pharmacologic agents, nasal discharge and touch smears of nasal cavity mucosa were used as investigative parameters in the study. The study was performed with the permission of the Biomedical Ethics Committee of the State Budgetary Educational Institution of Higher Professional Education «Pacific State Medical University» of the Ministry ofHealth of the Russian Federation. Results. A monthlong therapy with desloratadine enabled clinical control of the symptoms of mild and moderate persistent allergic rhinitis in primary school children in 92,8% of cases and allowed to stop local allergic inflammation intensity as was proved by increasing symptom-free number of days and the fact that symptomatic treatment was not required. The use of desloratadine in the course of the next three months ensured retention of the achieved control. Side and adverse effects in the given group were not registered.